Compare TKO Group Holdings Inc (TKO) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TKO Group Holdings Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? TKO Group Holdings Inc trades at $173.56 (market cap $12.71B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: TKO Group Holdings Inc is far larger — about 2.6× Travere Therapeutics Inc. Common Stock's market cap, and TKO Group Holdings Inc pays a 1.82% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold TKO Group Holdings Inc for 31 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TKO | TVTX | |
|---|---|---|
Market Cap | $12.71B | $4.88B |
Volume | 835,872 | 1,668,577 |
Sector | Media | Health |
52-Week High | $224.96 | $67.52 |
52-Week Low | $172.38 | $26.79 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $17.07B | $5.01B |
Dividend Yield | 1.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TKO trades at $173.86, near a 52-week low, with a bearish technical signal. The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year guidance. Revenue growth is solid, with 2026 projected at $5.3B, though profitability remains modest with a net margin of 4.33%. Analyst sentiment is overwhelmingly positive, with a consensus price target of $227.00 and 89% buy ratings, but recent institutional selling and technical weakness suggest near-term caution.
The outlook is cautiously optimistic; strong media rights and franchise value underpin long-term growth, but high valuation multiples and recent price decline highlight execution risks. Investors should weigh robust analyst confidence against technical bearishness and margin pressures.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
